No datasets match
- 1.affirm::DMSubject Demographics
- 2.affirm::RANDSubject Randomization
- 3.broom.helpers::supported_modelsListing of Supported Models
- 4.cards::ADAEExample ADaM Data
- 5.cards::ADLBExample ADaM Data
- 6.cards::ADSLExample ADaM Data
- 7.cards::ADTTEExample ADaM Data
- 8.cards::ADAEExample ADaM Data
- 9.cards::ADLBExample ADaM Data
- 10.cards::ADSLExample ADaM Data
- 11.cards::ADTTEExample ADaM Data
- 12.dcurves::df_binarySimulated data with a binary outcome
- 13.dcurves::df_case_controlSimulated data with a case-control outcome
- 14.dcurves::df_survSimulated data with a survival outcome
- 15.ggsurvfit::adtteExample phase III clinical trial data set
- 16.ggsurvfit::df_colonFormatted Copy of 'survival::colon'
- 17.ggsurvfit::df_lungFormatted Copy of 'survival::lung'
- 18.ggsurvfit::adtteExample phase III clinical trial data set
- 19.ggsurvfit::df_colonFormatted Copy of 'survival::colon'
- 20.ggsurvfit::df_lungFormatted Copy of 'survival::lung'
- 21.gtsummary::trialResults from a simulated study of two chemotherapy agents
- 22.pharmaversesdtm::aeAdverse Events
- 23.pharmaversesdtm::ae_ophthaAdverse Events for Ophthalmology
- 24.pharmaversesdtm::ag_neuroProcedure Agents Dataset-neuro
- 25.pharmaversesdtm::beBiospecimen Events
- 26.pharmaversesdtm::ce_vaccineClinical Events for Vaccine
- 27.pharmaversesdtm::cmConcomitant Medication
- 28.pharmaversesdtm::dmDemography
- 29.pharmaversesdtm::dm_metabolicDemographic Dataset-metabolic
- 30.pharmaversesdtm::dm_neuroDemographic Dataset-neuro
- 31.pharmaversesdtm::dm_pedsDemographic Dataset-pediatrics
- 32.pharmaversesdtm::dm_vaccineDemographics for Vaccine
- 33.pharmaversesdtm::dsDisposition
- 34.pharmaversesdtm::egElectrocardiogram
- 35.pharmaversesdtm::exExposure
- 36.pharmaversesdtm::ex_ophthaExposure for Ophthalmology
- 37.pharmaversesdtm::ex_vaccineExposures for Vaccine
- 38.pharmaversesdtm::face_vaccineFindings About Clinical Events for Vaccine
- 39.pharmaversesdtm::is_adaImmunogenicity Specimen Assessments for ADA
- 40.pharmaversesdtm::is_vaccineImmunogenicity Specimen Assessments for Vaccine
- 41.pharmaversesdtm::lbLaboratory Measurements
- 42.pharmaversesdtm::lb_metabolicLaboratory Measurements Dataset-metabolic
- 43.pharmaversesdtm::lb_neuroLaboratory Test Dataset-neuro
- 44.pharmaversesdtm::lb_onco_pcwg3Laboratory Measurements (PSA) for Oncology
- 45.pharmaversesdtm::mbMicrobiology Specimen
- 46.pharmaversesdtm::mhMedical History
- 47.pharmaversesdtm::msMicrobiology Susceptibility
- 48.pharmaversesdtm::nv_neuroNeurological Assessment Dataset-neuro
- 49.pharmaversesdtm::oe_ophthaOphthalmic Examinations for Ophthalmology
- 50.pharmaversesdtm::pcPharmacokinetic Concentrations
- 51.pharmaversesdtm::ppPharmacokinetic Parameters
- 52.pharmaversesdtm::qs_metabolicQuestionnaire Dataset-metabolic
- 53.pharmaversesdtm::qs_ophthaQuestionnaire for Ophthalmology
- 54.pharmaversesdtm::rs_oncoDisease Response for Oncology
- 55.pharmaversesdtm::rs_onco_ca125Disease Response (GCIG)
- 56.pharmaversesdtm::rs_onco_imwgDisease Response (IMWG)
- 57.pharmaversesdtm::rs_onco_irecistDisease Response (iRECIST) for Oncology
- 58.pharmaversesdtm::rs_onco_lymphomaDisease Response (Lymphoma Lugano 2014)
- 59.pharmaversesdtm::rs_onco_pcwg3Disease Response (PCWG3) for Oncology
- 60.pharmaversesdtm::rs_onco_recistDisease Response (RECIST 1.1) for Oncology
- 61.pharmaversesdtm::sc_ophthaSubject Characteristic for Ophthalmology
- 62.pharmaversesdtm::sdg_dbSDG
- 63.pharmaversesdtm::smq_dbStandardized MedDRA Queries
- 64.pharmaversesdtm::suppaeSupplemental Adverse Events
- 65.pharmaversesdtm::suppce_vaccineSupplemental Qualifiers for Clinical Events for Vaccine
- 66.pharmaversesdtm::suppdmSupplemental Demography
- 67.pharmaversesdtm::suppdm_vaccineSupplemental Qualifiers for Demographics for Vaccine
- 68.pharmaversesdtm::suppdsSupplemental Disposition
- 69.pharmaversesdtm::suppex_vaccineSupplemental Qualifiers for Exposures for Vaccine
- 70.pharmaversesdtm::suppface_vaccineSupplemental Qualifiers for Findings About for Clinical Events for Vaccine
- 71.pharmaversesdtm::suppis_vaccineSupplemental Qualifiers for Immunogenicity Specimen Assessments for Vaccine
- 72.pharmaversesdtm::suppnv_neuroSupplemental for Neurological Assessment Dataset-neuro
- 73.pharmaversesdtm::supprs_onco_ca125Supplemental Qualifiers for RS_ONCO_CA125
- 74.pharmaversesdtm::supprs_onco_imwgSupplemental Qualifiers for RS_ONCO_IMWG
- 75.pharmaversesdtm::supptr_oncoSupplemental Tumor Results for Oncology
- 76.pharmaversesdtm::svSubject Visits
- 77.pharmaversesdtm::tr_oncoTumor Results for Oncology
- 78.pharmaversesdtm::tr_onco_recistTumor Results (RECIST 1.1) for Oncology
- 79.pharmaversesdtm::tsTrial Design
- 80.pharmaversesdtm::tu_oncoTumor Identification for Oncology
- 81.pharmaversesdtm::tu_onco_recistTumor Identification (RECIST 1.1) for Oncology
- 82.pharmaversesdtm::vsVital Signs
- 83.pharmaversesdtm::vs_metabolicVital signs Dataset-metabolic
- 84.pharmaversesdtm::vs_pedsVital signs Dataset-pediatrics
- 85.pharmaversesdtm::vs_vaccineVital Signs for Vaccine
- 86.starter::project_templatesProject templates
- 87.tfrmt::data_aeAdverse Events Analysis Results Data
- 88.tfrmt::data_demogDemography Analysis Results Data
- 89.tfrmt::data_efficacyEfficacy Analysis Results Data
- 90.tfrmt::data_labsLabs Analysis Results Data
- 91.tidycmprsk::trialResults from a simulated study of two chemotherapy agents
- 92.tidycmprsk::trialResults from a simulated study of two chemotherapy agents